Title | Ado-trastuzumab emtansine-associated telangiectasias in metastatic breast cancer: a case series. |
Publication Type | Journal Article |
Year of Publication | 2014 |
Authors | Sibaud V, Niec RE, Schindler K, Busam KJ, Roché H, Modi S, Delord JPierre, Lacouture ME |
Journal | Breast Cancer Res Treat |
Volume | 146 |
Issue | 2 |
Pagination | 451-6 |
Date Published | 2014 Jul |
ISSN | 1573-7217 |
Keywords | Adult, Aged, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Breast Neoplasms, Female, Humans, Maytansine, Middle Aged, Neoplasm Metastasis, Skin, Telangiectasis, Trastuzumab |
Abstract | Treatment of HER2-positive metastatic breast cancer with ado-trastuzumab emtansine (T-DM1), a novel antibody-drug conjugate, has resulted in both improved progression-free and overall survival. Recognition and treatment of diverse adverse events related to T-DM1 is critical for safety and tolerability. The most frequent adverse events with T-DM1 include fatigue, diarrhea, anemia, elevated transaminases, and mild-to-moderate hemorrhagic events, which are thought to be related to induced thrombocytopenia. Here, we present five case series of cutaneous and mucosal telangiectasias, definitely related to T-DM1. The development of telangiectasias represents a newly recognized adverse effect of T-DM1. We provide description and timing of the telangiectasias and review the mechanisms that may explain the formation of these vascular lesions in association with T-DM1. Further, we describe associated bleeding events and propose that induced telangiectasias could represent an additional cause of T-DM1-associated hemorrhage. |
DOI | 10.1007/s10549-014-3001-z |
Alternate Journal | Breast Cancer Res. Treat. |
PubMed ID | 24929675 |
Grant List | T32GM007739 / GM / NIGMS NIH HHS / United States |
Submitted by kej2006 on June 6, 2018 - 4:11pm